Literature DB >> 20738305

Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis.

Mascha Schuurmans1, Jacoline E C Bromberg, Jeanette Doorduijn, Philip Poortmans, Martin J B Taphoorn, Tatjana Seute, Roelien Enting, Gustaaf van Imhoff, Yvette van Norden, Martin J van den Bent.   

Abstract

Elderly patients with primary central nervous ystem lymphoma (PCNSL) do not tolerate treatment with combined radio-chemotherapy well because of leuco-encephalopathy; they are usually treated initially with chemotherapy or radiotherapy alone. Little is known about the efficacy and toxicity of these treatments outside clinical studies. This study was a retrospective analysis of all patients aged 60 years or over who were admitted with PCNSL to one of five Dutch centers between 1998 and 2007. A total of 74 patients were identified. Twenty-nine were treated with radiotherapy only (Group A), in 36 the intended treatment was chemotherapy alone (Group B), and nine were planned to receive chemotherapy followed by radiotherapy (Group C). Median overall survival was 20 months; 4 months in patients with a Karnofsky performance status (KPS) <70, 25 months in patients with a KPS ≥ 70 (P < 0·001). Treatment modality was not an independent prognostic factor. Forty patients were treated with methotrexate 3 g/m(2) : there were two toxic deaths. Ten patients discontinued chemotherapy because of toxicity. Delayed encephalopathy was reported in 10 patients. In conclusion, community hospitals still frequently utilize whole brain radiotherapy in elderly PCNSL patients, though a majority tolerates chemotherapy well. Performance status was the most important variable determining prognosis. Short and long term toxicities must be weighed against possible clinical benefits of each treatment, making treatment decisions a highly individualized process.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20738305     DOI: 10.1111/j.1365-2141.2010.08328.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Pilot study of gamma-knife surgery-incorporated systemic chemotherapy omitting whole brain radiotherapy for the treatment of elderly primary central nervous system lymphoma patients with poor prognostic scores.

Authors:  Joon Cho; Jihye Kim; Hui Jin Ryu; Hong Gee Roh; Hyun Woo Chung; Young-Cho Koh; Mark Hong Lee; Yoon-Ho Ko; Sung-Yong Kim
Journal:  Med Oncol       Date:  2014-02-05       Impact factor: 3.064

Review 2.  First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.

Authors:  B Kasenda; A J M Ferreri; E Marturano; D Forst; J Bromberg; H Ghesquieres; C Ferlay; J Y Blay; K Hoang-Xuan; E J Pulczynski; A Fosså; Y Okoshi; S Chiba; K Fritsch; A Omuro; B P O'Neill; O Bairey; S Schandelmaier; V Gloy; N Bhatnagar; S Haug; S Rahner; T T Batchelor; G Illerhaus; M Briel
Journal:  Ann Oncol       Date:  2015-02-20       Impact factor: 32.976

3.  Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma.

Authors:  Simona Ruggieri; Roberto Tamma; Nicoletta Resta; Francesco Albano; Nicoletta Coccaro; Daria Loconte; Tiziana Annese; Mariella Errede; Giorgina Specchia; Rebecca Senetta; Paola Cassoni; Domenico Ribatti; Beatrice Nico
Journal:  Oncotarget       Date:  2017-05-09

4.  The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group.

Authors:  Kenichiro Asano; Yoji Yamashita; Takahiro Ono; Manabu Natsumeda; Takaaki Beppu; Kenichiro Matsuda; Masahiro Ichikawa; Masayuki Kanamori; Masashi Matsuzaka; Akira Kurose; Kiyoshi Saito; Yukihiko Sonoda; Kuniaki Ogasawara; Yukihiko Fujii; Hiroaki Shimizu; Hiroki Ohkuma; Chifumi Kitanaka; Takamasa Kayama; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2021-10-12       Impact factor: 3.402

Review 5.  Management of elderly patients with primary central nervous system lymphoma.

Authors:  Mariza Daras; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

6.  Radiotherapy as an alternative treatment option for primary central nervous system lymphoma patients who are noncandidates for chemotherapy.

Authors:  Yoo-Kang Kwak; Byung-Ock Choi; Kyu Hye Choi; Jong Hoon Lee; Soo Yoon Sung; Yun Hee Lee
Journal:  Oncotarget       Date:  2017-11-10

Review 7.  Primary CNS lymphoma.

Authors:  Elizabeth H Phillips; Christopher P Fox; Kate Cwynarski
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

8.  Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience.

Authors:  Michio Iwabuchi; Yuta Shibamoto; Chikao Sugie; Shiho Ayakawa; Hiroyuki Ogino; Fumiya Baba
Journal:  J Radiat Res       Date:  2015-12-09       Impact factor: 2.724

9.  Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.

Authors:  Yangying Zhou; Wei Liu; Zhijie Xu; Hong Zhu; Desheng Xiao; Weiping Su; Ruolan Zeng; Yuhua Feng; Yumei Duan; Jianhua Zhou; Meizuo Zhong
Journal:  Neoplasia       Date:  2018-09-15       Impact factor: 5.715

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.